These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19652644)

  • 1. A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments.
    Righi M; Giacomini A; Lavazza C; Sia D; Carlo-Stella C; Gianni AM
    Lab Invest; 2009 Sep; 89(9):1063-70. PubMed ID: 19652644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins.
    Yadav A; Kumar B; Teknos TN; Kumar P
    Mol Cancer Ther; 2011 Jul; 10(7):1241-51. PubMed ID: 21551262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?
    Schor-Bardach R; Alsop DC; Pedrosa I; Solazzo SA; Wang X; Marquis RP; Atkins MB; Regan M; Signoretti S; Lenkinski RE; Goldberg SN
    Radiology; 2009 Jun; 251(3):731-42. PubMed ID: 19474376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (3)D [corrected] quantification of tumor vasculature in lymphoma xenografts in NOD/SCID mice allows to detect differences among vascular-targeted therapies.
    Righi M; Giacomini A; Cleris L; Carlo-Stella C
    PLoS One; 2013; 8(3):e59691. PubMed ID: 23555747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression.
    Zhang L; Bhasin M; Schor-Bardach R; Wang X; Collins MP; Panka D; Putheti P; Signoretti S; Alsop DC; Libermann T; Atkins MB; Mier JW; Goldberg SN; Bhatt RS
    PLoS One; 2011 Apr; 6(4):e19144. PubMed ID: 21559452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.
    Wang X; Zhang L; Goldberg SN; Bhasin M; Brown V; Alsop DC; Signoretti S; Mier JW; Atkins MB; Bhatt RS
    J Transl Med; 2011 Dec; 9():220. PubMed ID: 22188900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
    Devapatla B; Sharma A; Woo S
    PLoS One; 2015; 10(9):e0139237. PubMed ID: 26414070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy.
    Tang TC; Man S; Xu P; Francia G; Hashimoto K; Emmenegger U; Kerbel RS
    Neoplasia; 2010 Nov; 12(11):928-40. PubMed ID: 21076618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vivo visualization of tumor microvessel density and response to anti-angiogenic treatment by high resolution MRI in mice.
    Ullrich RT; Jikeli JF; Diedenhofen M; Böhm-Sturm P; Unruh M; Vollmar S; Hoehn M
    PLoS One; 2011 May; 6(5):e19592. PubMed ID: 21573168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth.
    Kakodkar NC; Peddinti RR; Tian Y; Guerrero LJ; Chlenski A; Yang Q; Salwen HR; Maitland ML; Cohn SL
    Pediatr Blood Cancer; 2012 Oct; 59(4):642-7. PubMed ID: 22147414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels.
    Wang Z; Hu J; Qiu SJ; Huang XW; Dai Z; Tan CJ; Zhou J; Fan J
    Expert Opin Investig Drugs; 2011 Aug; 20(8):1039-45. PubMed ID: 21671804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenesis as a therapeutic target in urothelial carcinoma.
    Pinto A; Redondo A; Zamora P; Castelo B; Espinosa E
    Anticancer Drugs; 2010 Nov; 21(10):890-6. PubMed ID: 20729712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
    Wilhelm SM; Carter C; Tang L; Wilkie D; McNabola A; Rong H; Chen C; Zhang X; Vincent P; McHugh M; Cao Y; Shujath J; Gawlak S; Eveleigh D; Rowley B; Liu L; Adnane L; Lynch M; Auclair D; Taylor I; Gedrich R; Voznesensky A; Riedl B; Post LE; Bollag G; Trail PA
    Cancer Res; 2004 Oct; 64(19):7099-109. PubMed ID: 15466206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of antiangiogenic and antiproliferative effects of sorafenib by sequential histology and intravoxel incoherent motion diffusion-weighted imaging in an orthotopic hepatocellular carcinoma xenograft model.
    Yang SH; Lin J; Lu F; Han ZH; Fu CX; Lv P; Liu H; Gao DM
    J Magn Reson Imaging; 2017 Jan; 45(1):270-280. PubMed ID: 27299302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.
    Kim S; Yazici YD; Calzada G; Wang ZY; Younes MN; Jasser SA; El-Naggar AK; Myers JN
    Mol Cancer Ther; 2007 Jun; 6(6):1785-92. PubMed ID: 17575107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
    Tang TC; Man S; Lee CR; Xu P; Kerbel RS
    Neoplasia; 2010 Mar; 12(3):264-74. PubMed ID: 20234820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Yang Y; Jiang H; Gao H; Kong J; Zhang P; Hu S; Shi B; Zhang P; Yao M; Li Z
    Neoplasia; 2012 Jun; 14(6):509-18. PubMed ID: 22787432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis in cancer: molecular mechanisms, clinical impact.
    Eichhorn ME; Kleespies A; Angele MK; Jauch KW; Bruns CJ
    Langenbecks Arch Surg; 2007 May; 392(3):371-9. PubMed ID: 17458577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor endothelial cells join the resistance.
    Dudley AC; Klagsbrun M
    Clin Cancer Res; 2009 Aug; 15(15):4787-9. PubMed ID: 19638456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.
    Carlo-Stella C; Locatelli SL; Giacomini A; Cleris L; Saba E; Righi M; Guidetti A; Gianni AM
    PLoS One; 2013; 8(4):e61603. PubMed ID: 23620775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.